Financial Disclosure

South San Francisco, Calif. – September 20, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Dualitas will screen over 300,000 bispecific antibody combinations for Roche

Under the agreement, Dualitas will use its proprietary DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, in what the company describes as one of the largest-scale bispecific discovery efforts undertaken. Roche will take over all subsequent preclinical development, regulatory, manufacturing and commercial activities for candidates that emerge from the collaboration.

Guadalajara, Mexico – September 20, 2026 -- Luca Mining Corp. has agreed to acquire the El Barqueño gold-silver-copper property in Jalisco, Mexico from a subsidiary of Agnico Eagle in a deal that could total up to $60 million in cash and shares plus royalty consideration.

Deal structure ties payments to drilling and production milestones

Luca will pay $10 million on closing through the issuance of its common shares, followed by up to $30 million in contingent payments: $15 million three months after the first drilling program begins, and $15 million upon commercial production. A further $20 million is tied to output, paid at $5 million for every 100,000 gold-equivalent ounces produced, capped at 400,000 ounces. Agnico Eagle will also hold a 2.0% net smelter return royalty on areas with currently defined mineral resources, which Luca can halve to 1% for $12.5 million.

Beijing – September 20, 2026 -- Investors in China's A-share market turned more cautious in the third quarter of 2026 even as corporate earnings began to recover, according to the latest CKGSB Investor Sentiment Survey covering the May-to-September 2026 period.

Investors cut return expectations and stock allocation plans

Only 58.6% of respondents expected A-share prices to rise, down 5.2 percentage points from April 2026. The expected rate of return fell 1.8 percentage points to negative 0.7%. Appetite for direct stock investment weakened sharply, with the net proportion of investors planning to increase stock holdings falling 7.3 percentage points to 10.7%; the equivalent figure for equity funds dropped 1.2 percentage points to 13.4%.

London – September 20, 2026 -- Confidence in alternative data budgets has reached its highest level in three years, with 97% of data buyers expecting spend to increase or hold steady over the next 12 months, according to Neudata's new report, The Future of Alternative and Market Data 2026.

Budget optimism climbs to a record high among data buyers

The figure is up from 89% last year, marking the strongest confidence Neudata has recorded since launching the survey three years ago. The report draws on 191 responses from data providers and buyers globally, the firm's largest sample to date, spanning quant, multi-strategy, discretionary and macro funds as well as AI research labs. Sixty percent of buyer respondents manage over $1 billion in assets.

LONDON – September 20, 2026 -- ECARX, the Nasdaq-listed automotive intelligence company, has surpassed 12 million vehicle deployments worldwide, spanning 18 OEMs, 28 brands and 159 markets.

ECARX added over 914,000 vehicle deployments in the first half of 2026

The company's in-vehicle technology stack now covers intelligent cockpit systems, vehicle software and OS-level solutions, centralized vehicle computing and ADAS. ECARX supports vehicle programs across brands including Geely, FAW-Hongqi, Lotus, Polestar, Volvo Cars, Renault and Volkswagen, spanning multiple vehicle platforms and technology domains.

ECARX is expanding beyond cockpit systems into integrated computing and software platforms

The broader technology footprint allows ECARX to support a wider range of vehicle functions as automakers shift toward AI-defined vehicle architectures.

Shanghai – September 20, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

Deal structure includes upfront payment, milestones and tiered royalties

The agreement grants Ona Therapeutics exclusive global rights to develop an ADC candidate using WuXi XDC's WuXiTecan-2 platform. The total potential deal value comprises an upfront payment plus development, regulatory and sales milestone payments, with WuXi XDC also eligible for tiered royalties on net sales once the resulting product reaches commercialization. WuXi XDC will additionally provide chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.

Shanghai – September 20, 2026 -- 111, Inc. (NASDAQ: YI) reported a net loss of RMB31.7 million (US$4.7 million) for the second quarter of 2026, more than four times the RMB7.3 million loss posted a year earlier, as the Shanghai-based healthcare platform accelerated its shift away from an asset-heavy distribution model.

Net revenue falls 28.3% as company sheds underperforming subsidiaries

Net revenue totaled RMB2.3 billion (US$339.0 million), down from RMB3.2 billion in the prior-year quarter. The company attributed the decline to last year's divestiture of several underperforming subsidiaries, part of a strategy to generate more service-based commission income and reduce operational and capital risk.

London – September 20, 2026 -- ACG Metals Limited (LSE: ACG) has more than quadrupled the post-tax net present value of its Gediktepe mine to approximately $1.2 billion, up from $265 million in 2024, following an updated Competent Person's Report prepared by SRK Consulting.

Ore Reserves jump 43% as copper content rises 34%

Total Ore Reserves increased to 26.5 million tonnes from 18.5 million tonnes in the 2024 CPR. In-situ reserves now contain 176kt of copper, 381kt of zinc, 535koz of gold and 20moz of silver, representing gains of 34%, 1%, 19% and 16% respectively versus the prior estimate.

Average annual output set to climb 60% to 36kt copper equivalent

Between 2027 and 2031, Gediktepe's average annual production is projected to reach approximately 36 kt CuEq, up from an original 20-25 kt target. Over an initial 11-year mine life, the operation is expected to produce a total of 352kt CuEq.

Stockholm – September 20, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Partnership clears regulatory hurdles first announced September 20, 2026

The deal, initially disclosed on September 20, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.

Hong Kong – September 20, 2026 -- Marvion Inc. (OTCQB: MVNC) reported first-half 2026 revenue of $1.86 million, up 21% from $1.53 million a year earlier, alongside a 62% increase in gross profit to $1.02 million, according to the Company's Form 10-Q for the six months ended September 20, 2026.

Operating income more than tripled to $286,524 in the first half

Income from operations rose from $85,430 in the first six months of 2025 to $286,524 in the same period of 2026. Net income for the period reached $174,891, compared with $114,778 a year earlier.

Second-quarter gross profit climbs 78% on 18% revenue growth

For the three months ended September 20, 2026, revenue totaled $1.05 million versus $889,768 in the prior-year quarter. Gross profit increased to $544,812 from $305,890, while operating income rose to $166,558 from $23,190. The Company reported quarterly net income of $97,282.